Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1143269 alone or with docetaxel in advanced solid tumors
NCT02439346Phase 1Terminated
- Sponsor
- Bayer
- Start
- Jun 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of bay1143269 in solid tumor (advanced stage) (4 arms), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose up to 2 years, Maximum Observed Drug Concentration and 1 more. Started Jun 2015; status: terminated.
02
Drugs
bay1143269
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02439346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02439346.